Valuation: COMPASS Pathways plc

Market Cap 1.94B 1.66B 1.55B 1.43B 2.68B 185B 2.73B 18.34B 7.18B 93B 7.28B 7.13B 307B P/E 2026 *
-6.51x
P/E 2027 * -8.36x
Enterprise Value 1.58B 1.36B 1.27B 1.16B 2.18B 151B 2.22B 14.94B 5.85B 75.79B 5.94B 5.81B 251B EV / Sales 2026 *
-
EV / Sales 2027 * 38x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.79%
1 week-1.48%
Current month+23.44%
1 month+13.44%
3 months+39.13%
6 months+69.61%
Current year+103.04%
1 week 13.06
Extreme 13.06
14.17
1 month 10.59
Extreme 10.59
14.59
Current year 4.88
Extreme 4.88
15.4
1 year 4.04
Extreme 4.04
15.4
3 years 2.25
Extreme 2.25
15.4
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 01/08/2022
Director of Finance/CFO 54 01/03/2024
Chief Tech/Sci/R&D Officer 66 01/05/2024
Director TitleAgeSince
Chairman 74 29/03/2024
Director/Board Member 69 01/04/2020
Director/Board Member 67 01/03/2021
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Tax

Chief Executive Officer

-5,962 0.0062%
26/3/26 Free

Chief Executive Officer

542,815 0.5658%
11/3/26 Tax

Chief Financial Officer

1,781 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%-1.48%+242.54%+70.02% 1.94B
+0.36%+1.50%+1.61%+23.73% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+1.30%+2.17%+4.07%+33.22% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +1.83%+1.66%+102.04%+122.31% 27.65B
Weighted average by Cap. +1.50%+2.35%+105.57%+153.84%

Financials

2026 *2027 *
Net sales - 39.7M 34.05M 31.8M 29.17M 54.86M 3.79B 55.76M 375M 147M 1.9B 149M 146M 6.29B
Net income -299M -256M -239M -219M -413M -28.54B -419M -2.82B -1.11B -14.31B -1.12B -1.1B -47.32B -252M -216M -202M -185M -348M -24.08B -354M -2.38B -932M -12.07B -946M -925M -39.92B
Net Debt -359M -308M -288M -264M -496M -34.31B -504M -3.39B -1.33B -17.21B -1.35B -1.32B -56.9B -432M -371M -346M -318M -597M -41.31B -607M -4.08B -1.6B -20.72B -1.62B -1.59B -68.5B
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
19/08/26 USD 14.01 +0.79% 2,836,065
18/08/26 USD 13.90 +1.31% 3,271,292
17/08/26 USD 13.72 +2.01% 1,795,274
14/08/26 USD 13.45 +1.20% 1,357,321
13/08/26 USD 13.29 -6.54% 2,387,060
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
14.01USD
Average target price
23.75USD
Spread / Average Target
+69.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPS Stock